在并发性疾病治疗中考虑认知障碍:满足我们最复杂客户需求的实用资源
1Carolyn Lemsky, is a clinical neuropsychologist and the clinical director of Community Head Injury Resource Services in Toronto, ON.
Healthcare quarterly (Toronto, Ont.)
|November 4, 2024
概括
认知障碍,通常源于脑损伤,显著影响心理健康和物质使用障碍治疗. 将认知支持整合到成计划中,对于有效的护理至关重要.
科学领域:
- 神经科学是一个神经科学.
- 成精神病学成精神病学
- 康复医学 康复医学 康复医学
背景情况:
- 心理健康,物质使用障碍和认知障碍之间的复杂关系在治疗中经常被忽视.
- 认知缺陷,特别是创伤性脑损伤 (TBI) 造成的认知缺陷,在成编程中提出了独特的挑战.
- 没有解决神经认知缺陷,主流的成治疗方法可能效果不佳.
研究的目的:
- 讨论中和心理健康中心 (CAMH) 与多伦多社区头部伤害资源服务 (CHIRS) 之间的合作伙伴关系的发现.
- 为项目管理人员提出建议,以改善同时出现精神健康,物质使用和认知障碍的人的护理.
主要方法:
- 成和脑损伤服务提供商之间的跨部门伙伴关系和合作.
- 对临床观察和项目交付挑战的审查.
- 根据确定的需求制定实际建议.
主要成果:
- 该研究强调了在成服务中识别和解决认知障碍的必要性.
- 为项目管理人员提出了四个关键建议.
- 有效的护理需要查,员工培训,跨部门合作伙伴关系和量身定制的计划.
结论:
- 对脑损伤的查对于识别神经认知障碍至关重要.
- 在识别和管理认知障碍方面,员工培训至关重要.
- 跨部门合作伙伴关系增强了对复杂客户的协作护理.
- 编程应包括对认知障碍患者有益的结构和干预措施.
相关概念视频
Alzheimer's Disease: Treatment
165
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
165
Alzheimer's Disease: Overview
449
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
449
Cognitive Therapy
145
Cognitive therapy, pioneered by Aaron T. Beck in the 1960s, is a structured approach to addressing psychological distress by focusing on the influence of thoughts on emotions and behaviors. All cognitive therapies involve the basic assumption that human beings have control over their feelings, and that how individuals feel about something depends on how they think about it. Unlike psychoanalytic methods that delve into unconscious processes or humanistic approaches emphasizing...
145
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
98
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
98
Dementia
97
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
97
Psychosis: Goals of Pharmacotherapy
104
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
104


